Is Lyka Labs overvalued or undervalued?
As of June 5, 2025, Lyka Labs is fairly valued with a PE Ratio of 50.21, an EV to EBITDA of 25.26, and a PEG Ratio of 0.11, indicating attractive growth potential compared to peers like Sun Pharma and Divi's Lab, despite a recent stock decline relative to the Sensex, while achieving a remarkable 568.77% return over the past five years.
As of 5 June 2025, the valuation grade for Lyka Labs has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 50.21, an EV to EBITDA of 25.26, and a PEG Ratio of 0.11, indicating a potentially attractive growth opportunity relative to its earnings.In comparison to its peers, Lyka Labs stands out with a PE Ratio that is higher than Sun Pharma's 35.25 and significantly lower than Divi's Lab's 79.33, which is categorized as very expensive. Other notable peers such as Cipla and Dr. Reddy's Labs are rated attractive with PE Ratios of 22.99 and 19.49, respectively. Despite a recent decline in stock performance relative to the Sensex over the year, Lyka Labs has shown a substantial 568.77% return over the past five years, reinforcing its potential as a fair investment in the pharmaceuticals and biotechnology sector.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
